The Pharma Closeout | Daily Pharmaceutical and Biotech News in 15 Minutes

BZ Group

Your daily pharmaceutical news briefing — FDA decisions, clinical trial results, biotech M&A, and drug pipeline updates in under 15 minutes, every weekday. Hosted by Alex Mercer and Maya Patel. Plus a Week in Review every Sunday synthesizing the week's biggest moves in pharma and biotech. Covering drug approvals, licensing and M&A deals, biopharma investing, and healthcare market intelligence. Smart, fast, and built for pharma and biotech professionals who need to stay ahead. Transcripts, deal intelligence, and the daily newsletter at https://thepharmacloseout.com/. Host voices are AI-created.

  1. 5d ago

    Daily Roundup | enGene Plans Bladder Cancer Filing & Mirum’s Second Hepatitis D Phase 3 Win

    enGene plans to start its FDA filing for detalimogene voraplasmid in bladder cancer by year-end after longer follow-up in a single-arm trial. Mirum’s brelovitug met the primary endpoint in a second Phase 3 hepatitis D trial, adding evidence for its planned US filing. Also covered: BioNTech’s $205 million deal for Scholar Rock’s priority review voucher, PepGen’s PGN-EDODM1 splicing data in myotonic dystrophy type 1, Oyster Therapeutics’ financing for its tau program, and Summit’s November 14 FDA goal date for ivonescimab plus chemotherapy in EGFR-mutated lung cancer. This is the delayed November 11, 2026 edition, released November 12. Alex Mercer and Maya Patel host. Sources enGene — LEGEND and filing plan https://investors.engene.com/English/investor/press-releases/news-details/2026/enGene-to-Initiate-a-BLA-Submission-for-Detalimogene-by-Year-End-and-Reports-New-Data-from-LEGEND-Trial-Pivotal-Cohort-1-in-BCG-Unresponsive-NMIBC/default.aspx Mirum — AZURE-4 and filing plan https://ir.mirumpharma.com/news/news-details/2026/Mirum-Pharmaceuticals-Announces-Primary-Endpoint-Met-in-AZURE-4-Phase-3-Study-and-Highlights-Long-Term-Brelovitug-Data-Presented-at-AASLD/default.aspx BioNTech — priority review voucher agreement https://www.biontech.com/us/en/home/mediaroom/news/statements/2026/11/BioNTech-to-Acquire-US-FDA-Priority-Review-Voucher.html PepGen — FREEDOM2-DM1 and partial clinical hold https://investors.pepgen.com/node/9531/html 4BIO Capital — Oyster Therapeutics financing https://www.4biocapital.com/single-post/oyster-series-a Summit Therapeutics — HARMONi and FDA goal date https://smmttx.com/news/press-releases/news-details/2026/Summit-Therapeutics-Reports-Financial-Results-and-Operational-Progress-for-the-Third-Quarter-and-Nine-Months-Ended-September-30-2026/

Ratings & Reviews

2.6
out of 5
5 Ratings

About

Your daily pharmaceutical news briefing — FDA decisions, clinical trial results, biotech M&A, and drug pipeline updates in under 15 minutes, every weekday. Hosted by Alex Mercer and Maya Patel. Plus a Week in Review every Sunday synthesizing the week's biggest moves in pharma and biotech. Covering drug approvals, licensing and M&A deals, biopharma investing, and healthcare market intelligence. Smart, fast, and built for pharma and biotech professionals who need to stay ahead. Transcripts, deal intelligence, and the daily newsletter at https://thepharmacloseout.com/. Host voices are AI-created.

You Might Also Like